Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 3/20 | 0.34 |
| ▸ | PGK2 | P07205 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4124282 | 0.91 | ADORA2A (0.55) | ADORA2AADORA3ADORA2BADORA1PGK1 | |
| SCHEMBL1402039 | 0.88 | ADORA2A (0.50) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4110157 | 0.87 | ADORA3 (0.41) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4113502 | 0.85 | ADORA2A (0.42) | ADORA2AADORA3KDM4ENPC1MAPT | |
| SCHEMBL1402061 | 0.84 | ADORA2A (0.51) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4117867 | 0.83 | ADORA2A (0.63) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4110298 | 0.83 | ADORA2A (0.51) | ADORA2AADORA3 | |
| SCHEMBL4125022 | 0.83 | ADORA2A (0.47) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4124595 | 0.82 | ADORA3 (0.38) | ADORA2AADORA3ADORA1 | |
| SCHEMBL241328 | 0.81 | ADORA3 (0.37) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA2A 2082/4885ADORA3 554/4885ADORA2B 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.